Research in obese rhesus macaques treated with a selective MC4R agonist for 8 weeks showed 13.5% body weight reduction, with transient decreases in food intake (35% reduction) but persistent effects on adiposity and metabolic parameters
Notably, the secondary composite renal outcome (new macroalbuminuria, a sustained decline in eGFR of 30% from baseline, or chronic renal replacement therapy) occurred less often in patients assigned to dulaglutide than in those assigned to placebo, which was statistically significant (HR, 0.85
The SCALE Obesity and Prediabetes trial (N=3,731) showed participants who discontinued liraglutide 3.0 mg after 56 weeks regained roughly 50% of their lost weight within 12 weeks [1]
Nutritionists remind us that diet is still key, but injections are a safe option when food or supplements on their own arent enough
These two conditions are often linked, and managing one can help improve the other